cas 2446818-55-7|| where to buy 3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]propanoic acid

Название продукции:3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]propanoic acid

IUPAC Name:3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]propanoic acid

: CAS：2446818-55-7; Молекулярная формула：C17H12F3NO2; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM1075856-1g	in stock	ǠȤœƚ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2446818-55-7 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:2446818-55-7; Молекулярная формула:C17H12F3NO2; Точка плавления:-; Smiles-код:C1=CC(=CC=C1C2=C(C3=C(N2)C(=CC(=C3)F)F)CCC(=O)O)F; Плотность:

: Номер в каталоге:CM1075856; Молекулярная масса:319.28; Точка кипения:; Номер Mdl:; Хранение:

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: VX-147; Vertex Pharmaceuticals announced that inaxaplin (VX-147) , a first-in-class molecule has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD. In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.